Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Tillotts Pharma AG, part of the Japanese Zeria Group, launched Octasa® 800mg (mesalazine) delayed-release tablets, as first-line treatment for moderately active ulcerative colitis (UC) in Canada.
read more
Adult multivitamins accounted for the largest piece of the supplements marketing pie, at about 40 percent of the global vitamin supplements industry. The vitamin sector as a whole generated $47.9B in 2021, and is projected to reach $98.6B by 2031, manifesting a CAGR of 7.6% from 2022 to 2031, according to a report from Allied Market Research.
read more
The global antifungal agents market is anticipated to grow at a significant CAGR of nearly 3.5% during the forecast period, according to a report from Research & Markets. Antifungal agents prevent and destroy the growth of fungi that are responsible for several diseases such as aspergillosis, ringworm, and skin infection, among others. Antifungal ...
read more
The pharmaceutical excipients market is projected to reach $11.5B by 2027 from $8.6B in 2022, at a CAGR of 5.9% during the forecast period, according to a report by Research & Markets.
read more
The global overactive bladder treatment market size was worth $4.3B in 2021 and is projected to reach $ 5.3B by 2028 at a CAGR of 3.1% by 2028, according to a report by The Insight Partners.
read more
Catalent purchased Metrics Contract Services, a Contract Development and Manufacturing Organization (CDMO) with a facility in Greenville, North Carolina, for $475 million from Mayne Pharma Group Limited.
read more
The global nutraceuticals market is expected to grow at a CAGR of 9.07% and reach $446.35B in 2027, according to a report by Research & Markets.
read more
Roquette, a producer of plant-based ingredients and a provider of pharmaceutical and nutraceutical excipients, will launch two mannitol products at CPHI.
read more
Cambrex announced it is investing in a new, 21,000-square-foot research and development facility in Minneapolis, expanding its capacity for small molecule development and manufacturing.
read more
The global smoking cessation and nicotine de-addiction products industry generated $20B in 2021, and is anticipated to generate $54.7B by 2031, witnessing a CAGR of 10.6% from 2022 to 2031, according to a report from Allied Market Research.
read more
Vivera announced the expansion of its exclusive global license to the TABMELT® platform for pharmaceutical use in Israel. This latest patent allowance by the Israel Patent Office (ILPO) follows international TABMELT patent grants in Canada, Russia, Australia, and the United Kingdom.
read more
Paratek Pharmaceuticals announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone follows a successful technology transfer by Paratek and its tablet manufacturing partners in the United States and Europe.
read more
Glenmark Pharmaceuticals announced the launch of Fingolimod Capsules, 0.5 mg, the generic version of Gilenya®1 Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.
read more
The China pharmaceutical contract manufacturing market is projected to grow at a CAGR of around 12.1% from 2022 through 2028. The major factor that drives the growth of the market includes the major companies in the pharmaceutical contract manufacturing market are expanding their manufacturing capacity in China.
read more
Ascletis Pharma announced that the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for COVID-19, has been filed to the U.S. Food and Drug Administration (FDA) after the Pre-IND consultation.
read more